|
Malignant neoplasm of urinary bladder
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
GSTM1 and NAT-2 deficient genotypes were found to be independently associated with the risk of bladder cancer (odds ratios 2.87 and 2.64, respectively).
|
12552997 |
2003 |
|
Malignant neoplasm of urinary bladder
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
GSTM1-negative, GSTT1-positive, and hOGG1 Ser326Ser and Ser326Cys genotypes are risk factors for bladder cancer (P = 0.020, P = 0.044, and P = 0.012, respectively).
|
15667866 |
2005 |
|
Malignant neoplasm of urinary bladder
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
GSTM1 polymorphism (but not CYP2E1 RsaI polymorphism) appears to contribute to the etiology of bladder cancer in a south-eastern Chinese population.
|
18304215 |
2008 |
|
Malignant neoplasm of urinary bladder
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
GSTM1 and NAT2 polymorphisms and colon, lung and bladder cancer risk: a case-control study.
|
19443391 |
2009 |
|
Malignant neoplasm of urinary bladder
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
GSTM1-null and GSTA1-low activity genotypes are associated with enhanced oxidative damage in bladder cancer.
|
23394311 |
2013 |
|
Malignant neoplasm of urinary bladder
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
GSTM1 deletion status and UGT1A1*28 rs8175347 genotypes were assessed in 189 non-muscle-invasive bladder cancers (NMIBC) patients with pTa (77.2%) and pT1 (22.8%) tumors and a mean follow-up of 5.6 years, to investigate whether two common functional polymorphisms in GSTM1 and UGT1A1 genes and smoking history are associated with recurrence-free survival of patients with NMIBC.
|
26645279 |
2016 |
|
Malignant neoplasm of urinary bladder
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
A greater reduction in bladder cancer risk was observed among current-smokers (OR: 0.43; 95% CI: 0.27-0.71) and carriers of GSTM1-null (homozygous absence) genotypes (OR: 0.43; 95% CI: 0.22-0.85).
|
20732908 |
2010 |
|
Malignant neoplasm of urinary bladder
|
0.400 |
Biomarker
|
disease |
BEFREE |
A lack of GSTM1 was associated with tobacco smoke-induced lung and bladder cancer.
|
9751255 |
1998 |
|
Malignant neoplasm of urinary bladder
|
0.400 |
Biomarker
|
disease |
CTD_human |
A multi-stage genome-wide association study of bladder cancer identifies multiple susceptibility loci.
|
20972438 |
2010 |
|
Malignant neoplasm of urinary bladder
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
A significantly higher BC risk was associated with GSTM1 null genotype after adjusting to age, sex and smoking habit (OR 1.85, 95 % CI 1.30-2.62; P = 0.001).
|
24919441 |
2014 |
|
Malignant neoplasm of urinary bladder
|
0.400 |
Biomarker
|
disease |
BEFREE |
After decades of research using a candidate gene approach, only NAT2 and GSTM1 have consistently been demonstrated to be germline genetic susceptibility markers for urinary bladder cancer (UBC).
|
20919828 |
2010 |
|
Malignant neoplasm of urinary bladder
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Also, elevated bladder cancer risks associated with GSTM1 and GSTT1 null genotypes were found in smokers.
|
15219943 |
2004 |
|
Malignant neoplasm of urinary bladder
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Among Korean subjects, GSTM1 null genotype was a significant risk factor for bladder cancer.
|
10840461 |
2000 |
|
Malignant neoplasm of urinary bladder
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Among the low-penetrant genes, the variants within the genes encoding metabolic enzymes have been consistently associated with susceptibility to bladder cancer and the evidence is compelling for NAT2 slow acetylator and GSTM1 null genotypes.
|
21738036 |
2011 |
|
Malignant neoplasm of urinary bladder
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Among women, the GSTM1 null genotype was associated with an elevated bladder cancer risk only among smokers (OR 2.3; 95% CI 1.1-4.5 in ever smokers versus OR 0.9; 95% CI 0.3-2.5 in never smokers).
|
15694665 |
2005 |
|
Malignant neoplasm of urinary bladder
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
An elevated relative bladder cancer risk of GSTM1 null genotype carriers was indicated by comparison of this background with the data of the bladder cancer cases (OR = 1.81; 95% CI [1.10, 2.98]; p = 0.019).
|
9010594 |
1996 |
|
Malignant neoplasm of urinary bladder
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Aromatic amines (AAs) and polycyclic aromatic hydrocarbons (PAHs) are carcinogens present in tobacco smoke and functional polymorphisms in NAT2 and GSTM1 metabolizing genes are associated with increased bladder cancer risk.
|
18632753 |
2008 |
|
Malignant neoplasm of urinary bladder
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Besides, meaningful association between individuals who carried the GSTM1 null genotype and increased BCa risk was detected (OR = 1.39, 95%CI 1.28-1.51).
|
27631264 |
2016 |
|
Malignant neoplasm of urinary bladder
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
By combining relative risks and genotype frequencies we have computed theoretical attributable risks for lung and bladder cancers and the CYP1A1 Msp1, CYP1A1 Exon 7, GSTM1 and NAT2*5 genotypes, among Caucasians and among Asians.
|
12505352 |
2002 |
|
Malignant neoplasm of urinary bladder
|
0.400 |
Biomarker
|
disease |
BEFREE |
CNV callings provided by TaqMan and MLPA were highly concordant and replicated the association between GSTM1 and bladder cancer.
|
22817656 |
2012 |
|
Malignant neoplasm of urinary bladder
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Combination of the high-risk genotypes (GSTM1 null + GSTT1 null + GSTP1 313 A/G or G/G) demonstrated further increase in the BC risk (OR = 6.64, 95 %CI = 3.63-12.16).
|
23054023 |
2013 |
|
Malignant neoplasm of urinary bladder
|
0.400 |
Biomarker
|
disease |
BEFREE |
Data indicate that GSTM1 is a susceptibility factor for environmentally triggered bladder cancer rather than for smoking-mediated bladder cancer.
|
28696897 |
2017 |
|
Malignant neoplasm of urinary bladder
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Furthermore, individuals presenting the homozygous wild type of GSTM1 and GSTM3 are significantly protected against bladder cancer.
|
11173863 |
2000 |
|
Malignant neoplasm of urinary bladder
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Furthermore, we found that NAT2 slow acetylator individuals temporarily carrying wild-type GSTT1 or GSTM1 null genotypes have a strong increased risk of bladder cancer (OR= 26 and 22.17, respectively).
|
19380028 |
2009 |
|
Malignant neoplasm of urinary bladder
|
0.400 |
Biomarker
|
disease |
BEFREE |
Gender-specific effects of NAT2 and GSTM1 in bladder cancer.
|
10845567 |
2000 |